Effects of percutaneous lower-extremity arterial interventions on endothelial function and inflammation response in patients with both type 2 diabetes and lower-extremity peripheral arterial disease.
BACKGROUND
The high incidence and damage of PAD in people with diabetes has aroused wide attention. We aimed to examine effects of percutaneous lower-extremity arterial interventions (PLEAIs) on endothelial function and inflammation response in type 2 diabetes (T2D) patients with lower-extremity peripheral arterial disease (PAD).


METHODS
78 T2D inpatients with PAD were selected into the treatment group. Their venous levels of von Willebrand Factor (vWF) and high sensitivity C reactive protein (hsCRP) were measured. Blood samples were collected from the arterial sheath for vWF and hsCRP tests. Venous levels of vWF and hsCRP were monitored at 24 hours, 48 hours, 1 week, and 2 weeks post PLEAIs.


RESULTS
Prior to PLEAIs, venous levels of vWF and hsCRP in the treatment group were significantly higher than the control group. The arterial levels of vWF and hsCRP were 117.9%±15.1% and 5.19±0.76 mg/L in the control group, while those levels in the treatment group before intervention were also significantly higher than in the control group. In the treatment group prior to inventions, vWF and hsCRP levels of arterial ischemic regions were significantly higher than the non-ischemic regions. The vWF level of arterial ischemic regions after treatment was significantly higher than that prior to treatment.


CONCLUSIONS
PLEAIs applied to those patients may lead to worse endothelial dysfunction and activated inflammatory response during treatment and 1 week after treatment, which indicates an emerging necessary of early protection or care on endothelial function and inflammatory reaction during and post PLEAIs.
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Yaping
Y
Du
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Fujun
F
Wang
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Huiqing
H
Qi
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Haixia
H
Ding
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Lin
L
Hou
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Qian
Q
Gao
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Miao
M
Tan
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Yueqin
Y
Liu
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Na
N
Xing
Department of Endocrinology, Fourth Hospital of Hebei Medical University Hebei 050011, China.
Jin
J
Sun
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D003925:Diabetic Angiopathies / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000503:physiopathology; D057510:Endovascular Procedures / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000378:metabolism*
D015415:Biomarkers; D018836:Inflammation Mediators; D014841:von Willebrand Factor; D002097:C-Reactive Protein
Type 2 diabetes; high-sensitivity C reaction protein; lower-extremity peripheral arterial lesions; percutaneous lower-extremity arterial intervention; von Willebrand Factor